Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,136.01
    +57.15 (+0.71%)
     

  • Bitcoin USD

    64,587.96
    +863.51 (+1.36%)
     

  • CMC Crypto 200

    1,338.67
    -57.87 (-4.01%)
     

  • S&P 500

    5,103.24
    +54.82 (+1.09%)
     

  • Dow

    38,276.89
    +191.09 (+0.50%)
     

  • Nasdaq

    15,915.94
    +304.18 (+1.95%)
     

  • Gold

    2,352.50
    +10.00 (+0.43%)
     

  • Crude Oil

    84.06
    +0.49 (+0.59%)
     

  • 10-Yr Bond

    4.6550
    -0.0510 (-1.08%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

H.C. Wainwright Sticks to Their Buy Rating for Kadmon Holdings

Investing.com
·1-min read


H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kadmon Holdings (NYSE:KDMN) on Monday, setting a price target of $25, which is approximately 470.78% above the present share price of $4.38.

Fein expects Kadmon Holdings to post earnings per share (EPS) of -$0.09 for the second quarter of 2020.

The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Kadmon Holdings, with an average price target of $14.33.
The analysts price targets range from a high of $25 to a low of $8.

In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $4.4 million and a net profit of -$18.27 million. The company's market cap is $700.06 million.

ADVERTISEMENT

According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is a 5-star analyst with an average return of 10.6% and a 47.1% success rate.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.